Luo, F.; Tang, Y.; Zheng, L.; Yang, Y.; Gao, H.; Tian, S.; Chen, H.; Tang, C.; Tang, S.; Man, Q.;
et al. Isoliquiritigenin Inhibits the Growth of Colorectal Cancer Cells through the ESR2/PI3K/AKT Signalling Pathway. Pharmaceuticals 2024, 17, 43.
https://doi.org/10.3390/ph17010043
AMA Style
Luo F, Tang Y, Zheng L, Yang Y, Gao H, Tian S, Chen H, Tang C, Tang S, Man Q,
et al. Isoliquiritigenin Inhibits the Growth of Colorectal Cancer Cells through the ESR2/PI3K/AKT Signalling Pathway. Pharmaceuticals. 2024; 17(1):43.
https://doi.org/10.3390/ph17010043
Chicago/Turabian Style
Luo, Fenglin, Yimeng Tang, Lin Zheng, Ying Yang, Haoyue Gao, Shiya Tian, Hongyu Chen, Chenxi Tang, Shanshan Tang, Qiong Man,
and et al. 2024. "Isoliquiritigenin Inhibits the Growth of Colorectal Cancer Cells through the ESR2/PI3K/AKT Signalling Pathway" Pharmaceuticals 17, no. 1: 43.
https://doi.org/10.3390/ph17010043
APA Style
Luo, F., Tang, Y., Zheng, L., Yang, Y., Gao, H., Tian, S., Chen, H., Tang, C., Tang, S., Man, Q., & Wu, Y.
(2024). Isoliquiritigenin Inhibits the Growth of Colorectal Cancer Cells through the ESR2/PI3K/AKT Signalling Pathway. Pharmaceuticals, 17(1), 43.
https://doi.org/10.3390/ph17010043